BOSTON & SHREVEPORT, La.--(BUSINESS WIRE)--Embera NeuroTherapeutics dosed first patient in Phase 1 clinical trial to test EMB-001 for the potential treatment of cocaine use disorder and other addictions such as tobacco use disorder.